INDEMNITY AGREEMENTIndemnity Agreement • August 27th, 2018 • Metacrine, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledAugust 27th, 2018 Company Industry JurisdictionTHIS INDEMNITY AGREEMENT (this “Agreement”) dated as of , 20 , is made by and between METACRINE, INC., a Delaware corporation (the “Company”), and (“Indemnitee”).
AMENDED AND RESTATED EXCLUSIVE FXR LICENSE AGREEMENTExclusive FXR License Agreement • August 27th, 2018 • Metacrine, Inc. • Pharmaceutical preparations • California
Contract Type FiledAugust 27th, 2018 Company Industry JurisdictionThis Amended and Restated Exclusive FXR License Agreement (the “Agreement”) is made and entered into as of November 10, 2016 (the “Effective Date”) by and between The Salk Institute for Biological Studies, San Diego, California, a nonprofit public benefit corporation organized under the laws of the State of California (“Salk”) with an address at 10010 North Torrey Pines Road, San Diego, California 92037 and Metacrine, Inc., a corporation organized under the laws of the State of Delaware (“Licensee”) with an address at 12780 El Camino Real, Suite #301, San Diego, CA 92130, and together with the Amended and Restated Exclusive FGF1 Agreement (the “FGF1 Agreement”); amends and restates in its entirety the EXCLUSIVE PATENT LICENSE AGREEMENT between Salk and Licensee dated January 12, 2015 (the “Original Effective Date”), as amended December 21, 2015 (Salk Reference Number 2016- 0241, the “First Amendment”) (as so amended Salk Reference Number 2015-0002, the “Original License Agreement”), ef
SECOND AMENDMENT TO AMENDED AND RESTATED EXCLUSIVE FXR LICENSE AGREEMENTExclusive FXR License Agreement • August 27th, 2018 • Metacrine, Inc. • Pharmaceutical preparations
Contract Type FiledAugust 27th, 2018 Company IndustryThis Second Amendment to Amended and Restated Exclusive FXR License Agreement (this “Amendment”) is made and effective July 25, 2018 (the “Amendment Effective Date”) by and between The Salk Institute for Biological Studies (“Salk”) and Metacrine, Inc. (“Licensee”), and amends the Amended and Restated Exclusive FXR License Agreement between the Parties effective November 10, 2016 (the “License”). Salk and Licensee shall be individually referred to herein as a “Party” and collectively as the “Parties.” All capitalized terms used herein and not otherwise defined shall have the meaning assigned in the License.
FIRST AMENDMENT TO LICENSE AGREEMENT ID 2017-0184License Agreement • August 27th, 2018 • Metacrine, Inc. • Pharmaceutical preparations
Contract Type FiledAugust 27th, 2018 Company IndustryThis First Amendment to License Agreement ID 2017-0184 between the parties dated November 10, 2016 (this “First Amendment”) is effective Feb 4, 2017 (the “First Amendment Date”), by and between The Salk Institute for Biological Studies, San Diego, California, a nonprofit public benefit corporation organized and existing under the laws of the State of California, USA, having an office at 10010 North Torrey Pines Road, La Jolla, CA 92037 (“Salk”) and Metacrine, Inc., having a principal place of business at 12780 El Camino Real, Suite 301, San Diego, CA 92130 (“Licensee”).